Studies on drug metabolism and liver ultrastructure after conjoint treatment with pregnenolone-16alpha-carbonitrile and dl-ethionine. 1977

B D Garg, and P Kourounakis, and B Tuchweber, and S Szabo, and K Kovacs

Zoxazolamine paralysis, hexobarbital anesthesia and digitoxin convulsions were diminished in rats by 3 days of pretreatment with pregnenolone-16alpha-carbonitrile (PCN). Simultaneous injection of dl-ethionine did not block this effect of PCN. Dl-Ethionine decreased, while PCN or PCN + ethionene increased, zoxazolamine metabolism by the 9,000g supernatant fraction of the liver. Dl-ethionine neutralized the influence of PCN and phenobarbital on zoxazolamine metabolism in rats that were pretreated with PCN or phenobarbital for 1 day, and it inhibited the action of phenobarbital on hexobarbital anesthesia. PCN augmented the liver weight of animals given dl-ehtionine whereas dl-ethionine in itself did not. PCN produced SER proliferation in hepatocytes and dl-ethionine caused lipid accumulation, SER proliferation and myelin-figure formation. When administered conjointly, these compounds had an additive effect on the liver cell ultrastructure.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008854 Microscopy, Electron Microscopy using an electron beam, instead of light, to visualize the sample, thereby allowing much greater magnification. The interactions of ELECTRONS with specimens are used to provide information about the fine structure of that specimen. In TRANSMISSION ELECTRON MICROSCOPY the reactions of the electrons that are transmitted through the specimen are imaged. In SCANNING ELECTRON MICROSCOPY an electron beam falls at a non-normal angle on the specimen and the image is derived from the reactions occurring above the plane of the specimen. Electron Microscopy
D010243 Paralysis A general term most often used to describe severe or complete loss of muscle strength due to motor system disease from the level of the cerebral cortex to the muscle fiber. This term may also occasionally refer to a loss of sensory function. (From Adams et al., Principles of Neurology, 6th ed, p45) Palsy,Plegia,Todd Paralysis,Todd's Paralysis,Palsies,Paralyses,Paralysis, Todd,Paralysis, Todd's,Plegias,Todds Paralysis
D010634 Phenobarbital A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. Phenemal,Phenobarbitone,Phenylbarbital,Gardenal,Hysteps,Luminal,Phenobarbital Sodium,Phenobarbital, Monosodium Salt,Phenylethylbarbituric Acid,Acid, Phenylethylbarbituric,Monosodium Salt Phenobarbital,Sodium, Phenobarbital
D011285 Pregnenolone Carbonitrile A catatoxic steroid and microsomal enzyme inducer having significant effects on the induction of cytochrome P450. It has also demonstrated the potential for protective capability against acetaminophen-induced liver damage. PCN,Pregnenolone 16 alpha-Carbonitrile,Pregnenolone Carbonitrile, (3 beta)-Isomer,Pregnenolone Carbonitrile, (3 beta,16 beta)-Isomer,16 alpha-Carbonitrile, Pregnenolone,Carbonitrile, Pregnenolone,Pregnenolone 16 alpha Carbonitrile
D004074 Digitoxin A cardiac glycoside sometimes used in place of DIGOXIN. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665) Coramedan,Digimed,Digimerck,Digitaline Nativelle,Digitoxin AWD,Digitoxin Bürger,Digitoxin Didier,Digitoxin-Philo,Digophton,AWD, Digitoxin,Bürger, Digitoxin,Didier, Digitoxin,Digitoxin Philo,Nativelle, Digitaline
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D004364 Pharmaceutical Preparations Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form. Drug,Drugs,Pharmaceutical,Pharmaceutical Preparation,Pharmaceutical Product,Pharmaceutic Preparations,Pharmaceutical Products,Pharmaceuticals,Preparations, Pharmaceutical,Preparation, Pharmaceutical,Preparations, Pharmaceutic,Product, Pharmaceutical,Products, Pharmaceutical
D005001 Ethionine 2-Amino-4-(ethylthio)butyric acid. An antimetabolite and methionine antagonist that interferes with amino acid incorporation into proteins and with cellular ATP utilization. It also produces liver neoplasms.
D005260 Female Females

Related Publications

B D Garg, and P Kourounakis, and B Tuchweber, and S Szabo, and K Kovacs
January 1976, Acta hepato-gastroenterologica,
B D Garg, and P Kourounakis, and B Tuchweber, and S Szabo, and K Kovacs
January 1976, Arzneimittel-Forschung,
B D Garg, and P Kourounakis, and B Tuchweber, and S Szabo, and K Kovacs
March 1977, Biochemical pharmacology,
B D Garg, and P Kourounakis, and B Tuchweber, and S Szabo, and K Kovacs
January 1974, Acta anatomica,
B D Garg, and P Kourounakis, and B Tuchweber, and S Szabo, and K Kovacs
August 1975, Biochemical pharmacology,
B D Garg, and P Kourounakis, and B Tuchweber, and S Szabo, and K Kovacs
January 1974, Experimentelle Pathologie,
B D Garg, and P Kourounakis, and B Tuchweber, and S Szabo, and K Kovacs
November 1976, Research communications in chemical pathology and pharmacology,
B D Garg, and P Kourounakis, and B Tuchweber, and S Szabo, and K Kovacs
February 1975, The Journal of pharmacy and pharmacology,
B D Garg, and P Kourounakis, and B Tuchweber, and S Szabo, and K Kovacs
February 2005, Experimental and molecular pathology,
B D Garg, and P Kourounakis, and B Tuchweber, and S Szabo, and K Kovacs
January 1975, Acta anatomica,
Copied contents to your clipboard!